Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Inclusion Criteria:

- Male and female subjects ≥18 years of age

- Receiving chronic maintenance in-center hemodialysis (3 times per week) for end-stage
kidney disease

- Currently maintained on ESA therapy

- Mean screening Hb between 8.0 and 11.0 g/dL (inclusive)

Exclusion Criteria:

- Anemia due to a cause other than CKD or presence of active bleeding or recent blood
loss

- Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic
malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia

- Red blood cell transfusion within 4 weeks prior to or during screening

- Anticipated to recover adequate kidney function to no longer require hemodialysis
during study participation